+++
date = "2017-05-17"
title = "About me"
+++

I am lecturer at [Tallinn University of Technology](https://www.ttu.ee) (TTU), Estonia. 
I teach [Oncobiology](http://onkobioloogia.netlify.com) (_in estonian_) to master's students. 
Since 2016 I also teach [Reproducible Data Analysis in R](https://tpall.github.io/learn-r/) in University of Tartu, Estonia, for the [Graduate School in Biomedicine and Biotechnology](http://www.biomeddk.ut.ee/148881).
In August 2013 I received PhD in Gene technology from TTU. 
Before that from 2006 to 2015 I was senior researcher at Celecure Ltd. and then at Competence Centre for Cancer Research Ltd. (CCCR).
My research has been centered on the hyaluronan receptor CD44 and its role in angiogenesis.   

I am a big fan of [The Fall](http://thefall.org). 
I enjoy riding [mountain bike](https://scontent-arn2-1.xx.fbcdn.net/v/t31.0-8/13767362_278969895809400_9154439368527794396_o.jpg?oh=4f06acd28bca8417ea40f0790bfb8158&oe=59BDAAF6).


## Publications
1. [Pink, A; Školnaja, M; Päll, T; Valkna A. (2016) CD44 Controls Endothelial Proliferation and Functions as Endogenous Inhibitor of Angiogenesis. bioRxiv doi: 10.1101/049494.](http://biorxiv.org/content/biorxiv/early/2016/06/27/049494.full.pdf)
2. [Pink, A; Kallastu, A; Turkina, M; Školnaja, M; Kogerman, P; Päll, T; Valkna, A. (2014). Purification, Characterization and Plasma Half-Life of PEGylated Soluble Recombinant Non-HA-Binding CD44. BioDrugs, 28(4): 393-402. doi: 10.1007/s40259-014-0089-y.](https://link.springer.com/article/10.1007/s40259-014-0089-y)  
3. [Päll, T; Pink, A; Kasak, L; Turkina, M; Anderson, W; Valkna, A; Kogerman, P. (2011). Soluble CD44 Interacts with Intermediate Filament Protein Vimentin on Endothelial Cell Surface. PLoS ONE, 6(12), e29305.](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029305)   
4. [Päll, T; Gad, A; Kasak, L; Drews, M; Strömblad, S; Kogerman, P (2004). Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding. Oncogene, 23(47), 7874 - 7881.](http://www.nature.com/onc/journal/v23/n47/full/1208083a.html)  

## Supervised theses
- [Anne Pink (2016) The role of CD44 in the control of endothelial cell proliferation and angiogenesis.
Tallinn University of Technology. Supervisors: T. Päll, PhD and A. Valkna, PhD.](https://digi.lib.ttu.ee/i/?6805)

## Patents
- Päll, Taavi; Anderson, Wally; Kasak, Lagle; Pink, Anne; Kogerman, Priit; Allikas, Aire; Valkna, Andres. Methods of using vimentin to inhibit angiogenesis and endothelial cell prolifera- tion. United States Patent 8,524,666; September 3, 2013.  
- Strömblad, Staffan; Päll, Taavi; Kogerman, Priit. Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation. United States Patent 8,192,744. June 5, 2012.   
- Strömblad, Staffan; Kogerman, Priit; Päll, Taavi. New drug. WO2003018044. March 3, 2003  
